by Portfolio Grader | August 17, 2012 11:04 am
Six Pharmaceutical stocks are moving up in their overall rating this week, according to the Portfolio Grader database. Every one of these is graded an “A” (“strong buy”) or “B” overall (“buy”).
Allergan (NYSE:AGN) ups its rating to a B (“buy”) this week after earning a C (“hold”) in the week before. Allergan is a healthcare company focused on developing and commercializing pharmaceuticals, biologics, and medical devices. In Portfolio Grader’s specific subcategory of Equity, AGN also gets an A. For more information, get Portfolio Grader’s complete analysis of AGN stock.
XenoPort (NASDAQ:XNPT) earns a B this week, jumping up from last week’s grade of C. XenoPort is a biopharmaceutical company that focuses on developing and commercializing a portfolio of internally discovered product candidates for the potential treatment of neurological disorders. The stock price has risen 33.2% over the past month, better than the 5.7% increase the Nasdaq has seen over the same period of time. For more information, get Portfolio Grader’s complete analysis of XNPT stock.
This is a strong week for Cumberland Pharmaceuticals (NASDAQ:CPIX). The company’s rating climbs to B from the previous week’s C. Cumberland Pharmaceuticals engages in the acquisition, development, and commercialization of branded prescription products for the hospital acute care and gastroenterology markets primarily in the United States. For more information, get Portfolio Grader’s complete analysis of CPIX stock.
SciClone Pharmaceuticals‘s (NASDAQ:SCLN) gets a higher grade this week, advancing from a C last week to a B. SciClone Pharmaceuticals is a global biopharmaceutical company that acquires, develops, and commercializes specialist-oriented drugs. The stock has a trailing PE Ratio of 8.9. For more information, get Portfolio Grader’s complete analysis of SCLN stock.
This week, Acura Pharmaceuticals‘s (NASDAQ:ACUR) ratings are up from a C last week to a B. Acura Pharmaceuticals engages in the research, development, and manufacture of pharmaceutical product candidates utilizing its proprietary Aversion and Impede technologies. For more information, get Portfolio Grader’s complete analysis of ACUR stock.
This week, Sucampo Pharmaceuticals (NASDAQ:SCMP) pushes up from a C to a B rating. Sucampo Pharmaceuticals is a biopharmaceutical company focused on the discovery, development and commercialization of proprietary drugs based on prostones, a class of compounds derived from functional fatty acids that occur naturally in the human body. For more information, get Portfolio Grader’s complete analysis of SCMP stock.
Louis Navellier’s proprietary Portfolio Grader stock ranking system assesses roughly 5,000 companies every week based on a number of fundamental and quantitative measures. Stocks are given a letter grade based on their results — with A being “strong buy,” and F being “strong sell.” Explore the tool here.
Source URL: http://investorplace.com/2012/08/6-pharmaceutical-stocks-to-buy-now-agn-xnpt-cpix/
Short URL: http://invstplc.com/1nwnjNv
Copyright ©2014 InvestorPlace Media, LLC. All rights reserved. 700 Indian Springs Drive, Lancaster, PA 17601.